Caldwell Sutter Capital’s Pacific Biosciences PACB Stock Holding History

Caldwell Sutter Capital’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.6K	Hold	950	–	–	﹤0.01%	824
2026 Q1	$1.25K	Hold	950	–	–	﹤0.01%	801
2025 Q4	$1.78K	Hold	950	–	–	﹤0.01%	758
2025 Q3	$1.22K	Hold	950	–	–	﹤0.01%	787
2025 Q2	$1.18K	Hold	950	–	–	﹤0.01%	770
2025 Q1	$1.12K	Hold	950	–	–	﹤0.01%	787
2024 Q4	$1.74K	Buy	+950	New	+$1.85K	﹤0.01%	761

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Caldwell Sutter Capital's PACB Position: Q2 2026 in Review

Caldwell Sutter Capital held its Pacific Biosciences (PACB) position steady in Q2 2026 at 950 shares worth $1.6K. The position accounts for ﹤0.01% of the portfolio, ranked #824.

Caldwell Sutter Capital first reported a position in PACB in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.78K in Q4 2025. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

Caldwell Sutter Capital held 950 shares of Pacific Biosciences worth $1.6K as of Q2 2026.
Caldwell Sutter Capital left its Pacific Biosciences share count unchanged in Q2 2026.
Pacific Biosciences made up ﹤0.01% of Caldwell Sutter Capital's portfolio in Q2 2026, its #824 holding.
Caldwell Sutter Capital first reported a position in Pacific Biosciences in Q4 2024 and has held it in 7 quarters since.
Caldwell Sutter Capital's Pacific Biosciences position peaked at $1.78K in Q4 2025.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Caldwell Sutter Capital's 13F filing for Q2 2026, filed 5 Aug 2026.